At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SRPU Tradr 2X Long SRPT Daily ETF
Trading 03-27 12:42:02 EDT
10.20
-2.20
-17.74%
High12.04Low10.20Vol64.92K
Open12.04D1 Closing12.40Amplitude14.84%
Mkt Cap3.26MTradable Cap3.26MTotal Shares320.00K
T/O706.92KT/O Rate20.29%Tradable Shares320.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Deutsche ups Sarepta target, says 35% stock rally overdone
TIPRANKS  ·  03-26 20:40
Deutsche ups Sarepta target, says 35% stock rally overdone
Sarepta price target raised to $35 from $29 at Wedbush
TIPRANKS  ·  03-26 20:37
Sarepta price target raised to $35 from $29 at Wedbush
Sarepta Therapeutics, Inc. : Deutsche Bank Raises Target Price to $14 From $12
THOMSON REUTERS  ·  03-26 19:06
Sarepta Therapeutics, Inc. : Deutsche Bank Raises Target Price to $14 From $12
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)
TIPRANKS  ·  03-26 18:50
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Inc : Wedbush Raises Target Price to $35 From $29
THOMSON REUTERS  ·  03-26 18:45
Sarepta Therapeutics Inc : Wedbush Raises Target Price to $35 From $29
Sarepta price target raised to $13 from $9 at Citi
TIPRANKS  ·  03-26 17:56
Sarepta price target raised to $13 from $9 at Citi
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
Reuters  ·  03-26 15:38
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
Sarepta Therapeutics Inc : Piper Sandler Raises Target Price to $23 From $16
THOMSON REUTERS  ·  03-26 11:11
Sarepta Therapeutics Inc : Piper Sandler Raises Target Price to $23 From $16
ETF Daily | SRPU Soars 69%; FLYT Surges 37%; ARMG Jumps 33%; Space and Semiconductor Themes Lead
ETF Tracker  ·  03-26 11:00
ETF Daily | SRPU Soars 69%; FLYT Surges 37%; ARMG Jumps 33%; Space and Semiconductor Themes Lead
Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 And AMD: Why These 5 Stocks Are On Investors' Radars Today
Benzinga_recent_news  ·  03-26 09:25
Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 And AMD: Why These 5 Stocks Are On Investors' Radars Today
U.S. Small Caps Rise; Sarepta Therapeutics Climbs Highest
Dow Jones  ·  03-26 04:21
U.S. Small Caps Rise; Sarepta Therapeutics Climbs Highest
Sarepta price target raised to $25 from $20 at Morgan Stanley
TIPRANKS  ·  03-26 03:50
Sarepta price target raised to $25 from $20 at Morgan Stanley
Sarepta Therapeutics Up Over 30%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk
Dow Jones  ·  03-26 01:34
Sarepta Therapeutics Up Over 30%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk
These Stocks Are Today's Movers: Arm, Intel, Firefly Aerospace, Robinhood, Sarepta, JD.com, and More -- Barrons.com
Dow Jones  ·  03-26 00:24
These Stocks Are Today's Movers: Arm, Intel, Firefly Aerospace, Robinhood, Sarepta, JD.com, and More -- Barrons.com
Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. -- Barrons.com
Dow Jones  ·  03-26 00:17
Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. -- Barrons.com
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
TIPRANKS  ·  03-25 22:10
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
TIPRANKS  ·  03-25 21:55
Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
Amex Halt Add Info Lst 8.828000
THOMSON REUTERS  ·  03-25 21:30
Amex Halt Add Info Lst 8.828000
Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases
MT Newswires Live  ·  03-25 20:46
Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases
Shares of Sarepta Therapeutics up 3.2% Premarket After Muscle Disease Drugs Show Promise in Early-to-Mid Stage Trials
THOMSON REUTERS  ·  03-25 20:29
Shares of Sarepta Therapeutics up 3.2% Premarket After Muscle Disease Drugs Show Promise in Early-to-Mid Stage Trials

Introduction

Company Name.
Tradr 2X Long SRPT Daily ETF
Affiliated Markets:
CBOE
Listing Date:
--
Main Business:
Issue price:
--